link to webcast
Category: Webcast
2023 Half-year results and business update
link to webcast
New Leadership Structure to Accelerate the Development of its Innovative Immunotherapy Portfolio
link to webcast
2022 Full-year results and business update
Link to webcast
TG4050, First positive clinical data from Phase I clinical trials
link to webcast
First efficacy results of TG4001+avelumab in HPV16-positive cancers
https://channel.royalcast.com/webcast/transgene/20191003_1/
Transgene and Tasly Biopharmaceuticals conclude strategic agreements for the rights of TG6002 and TG1050 in Greater China
Webcast